Compare ClearPoint Neuro Inc (CLPT) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Charles Schwab Corporation Common Stock — how do they compare? ClearPoint Neuro Inc trades at $14.98 (market cap $454.21M), while Charles Schwab Corporation Common Stock trades at $108.61 (market cap $186.25B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 410.1× ClearPoint Neuro Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.19% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | SCHW | |
|---|---|---|
Market Cap | $454.21M | $186.25B |
Sector | Health | Financials |
52-Week High | $29.60 | $108.02 |
52-Week Low | $8.66 | $85.35 |
Enterprise Value | $488.79M | — |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
Charles Schwab (SCHW) trades at $108.63, up 0.59% today, approaching its all-time high of $109.05. The stock shows strong momentum with three consecutive quarterly earnings beats and bullish technical indicators. Revenue grew to $23.92B in 2025 with net income margin expanding to 38.79%. Recent news highlights institutional buying and positive analyst coverage, though an insider sale and ongoing litigation present minor concerns.
Outlook remains positive with analyst consensus target of $122.33 suggesting 12.6% upside. Strong earnings growth, improving cash flow trends, and market leadership position support further appreciation. Key risks include market sensitivity to interest rates, competitive pressures, and potential regulatory impacts from ongoing litigation. The stock offers growth potential but requires monitoring of macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
